首页> 外文期刊>Gastroenterology >Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management
【24h】

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management

机译:原发性硬化性胆管炎的发病机理及诊治进展

获取原文
获取原文并翻译 | 示例
           

摘要

Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
机译:1850年代中期首次描述的原发性硬化性胆管炎(PSC)是一种复杂的肝病,其表现形式不一。 PSC的特征是与胆道上皮的慢性炎症相关的慢性胆汁淤积,导致多灶性胆管狭窄,可影响整个胆道树。慢性炎症导致涉及肝实质和胆道树的纤维化,可导致肝硬化和恶性肿瘤。 PSC的病因尚不完全清楚,部分解释了这种情况缺乏有效的医学治疗方法。但是,我们已经开始更好地了解PSC的分子发病机理。对特定临床亚型及其进展模式的认识可以改善该疾病的表型和基因型分类。我们回顾了我们目前对这种神秘疾病的理解,并讨论了未来研究的重要课题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号